^
Association details:
| Biomarker: | BCL2 expression + MYC expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yinuokai (orelabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
Published date:
06/09/2023
Excerpt:
We aimed to analyze efficacy and safety of O plus R-CHOP-like (O+R-CHOP) for untreated non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) patients (pts)....Most had extranodal involvement (72.7%) and MYC/BCL2 double expression lymphoma (DEL, 54.5%)....By subgroup analysis of 11 pts after induction stage, pts with DEL had better mRR (100.0% vs. 75.0%) than non-DEL...pts with DEL and extranodal involvement had CRR of 100.0% and 75.0%, respectively...
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1002/hon.3165_659
Trial ID:
